UK markets open in 7 hours 50 minutes
NIKKEI 225
38,946.93 -122.75 (-0.31%) HANG SENG
19,220.62 -415.60 (-2.12%) CRUDE OIL
79.06 -0.20 (-0.25%) GOLD FUTURES
2,425.60 -0.30 (-0.01%) DOW
39,872.99 +66.22 (+0.17%) Bitcoin GBP
55,202.65 +308.33 (+0.56%)
Merck & Co., Inc. (6MK.F)
Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
At close: 08:00AM CEST
| Previous close | 120.80 |
| Open | 120.20 |
| Bid | 120.20 x 100000 |
| Ask | 120.40 x 100000 |
| Day's range | 120.20 - 120.20 |
| 52-week range | 90.70 - 123.20 |
| Volume | |
| Avg. volume | 345 |
| Market cap | 304.444B |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | 144.82 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.84 (2.35%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | N/A |
- Business Wire
Merck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline
RAHWAY, N.J., May 15, 2024--Merck to Present New Data at 2024 ASCO Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline
- Business Wire
Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma
RAHWAY, N.J., May 13, 2024--Merck Update on KeyVibe-010 Evaluating Coform of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients W/ Resected High-Risk Melanoma
- Business Wire
Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent
RAHWAY, N.J., May 09, 2024--Merck Provides Update on Phase 3 KEYNOTE-B21 Trial
© 2024 Yahoo. All rights reserved.